Sequential intensive chemotherapy followed by autologous or allogeneic transplantation for refractory lymphoma

References

• Philip T, Biron P. High-dose chemotherapy and autologous bone marrow transplantation in diffuse intermediate- and high-grade non-Hodgkin lymphoma. Crit Rev Oncol Hematol. 2002;41(2):213–223.
   PubMed Web of Science ®Google Scholar
• Barrington SF, Mikhaeel NG, Kostakoglu L, et al. Role of imaging in the staging and response assessment of lymphoma: consensus of the International Conference on Malignant Lymphomas Imaging Working Group. J Clin Oncol. 2014;32(27):3048–3058.
   PubMed Web of Science ®Google Scholar
• Sauter CS, Matasar MJ, Meikle J, et al. Prognostic value of FDG-PET prior to autologous stem cell transplantation for relapsed and refractory diffuse large B-cell lymphoma. Blood. 2015;125(16):2579–2581.
   PubMed Web of Science ®Google Scholar
• Ulaner GA, Goldman DA, Sauter CS, et al. Prognostic value of FDG PET/CT before allogeneic and autologous stem cell transplantation for aggressive lymphoma. Radiology. 2015;277(2):518–526.
   PubMed Web of Science ®Google Scholar
• Kenkre VP, Horowitz S, Artz AS, et al. T-cell-depleted allogeneic transplant without donor leukocyte infusions results in excellent long-term survival in patients with multiply relapsed Lymphoma. Predictors for survival after transplant relapse. Leuk Lymphoma. 2011;52(2):214–222.
   PubMed Web of Science ®Google Scholar
• Elstrom RL, Martin P, Ostrow K, et al. Response to second-line therapy defines the potential for cure in patients with recurrent diffuse large B-cell lymphoma: implications for the development of novel therapeutic strategies. Clin Lymphoma Myeloma Leuk. 2010;10(3):192–196.
   PubMed Web of Science ®Google Scholar
• Gergis U, Roboz G, Shore T, et al. A phase I study of CPX-351 in combination with busulfan and fludarabine conditioning and allogeneic stem cell transplantation in adult patients with refractory acute leukemia. Biol Blood Marrow Transplant. 2013;19(7):1040–1045.
   PubMed Web of Science ®Google Scholar
• Locke F, Agarwal R, Kunnavakkam R, et al. A novel clofarabine bridge strategy facilitates allogeneic transplantation in patients with relapsed/refractory leukemia and high-risk myelodysplastic syndromes. Bone Marrow Transplant. 2013;48(11):1437–1443.
   PubMed Web of Science ®Google Scholar
• Owattanapanich W, Ungprasert P, Wais V, et al. FLAMSA-RIC for stem cell transplantation in patients with acute myeloid leukemia and myelodysplastic syndromes: a systematic review and meta-analysis. J Clin Med. 2019;8(9):1437.
   Web of Science ®Google Scholar
• Thomas CM, Ippoliti C, Roboz GJ, et al. Clofarabine as a bridge to hematopoietic stem cell transplant. Leuk Lymphoma. 2017;58(1):230–232.
   PubMed Web of Science ®Google Scholar
• Zahid U, Akbar F, Amaraneni A, et al. A Review of Autologous Stem Cell Transplantation in Lymphoma. Curr Hematol Malig Rep. 2017;12(3):217–226.
   PubMed Web of Science ®Google Scholar
• Martin P, Chen Z, Cheson BD, et al. Long-term outcomes, secondary malignancies and stem cell collection following bendamustine in patients with previously treated non-Hodgkin lymphoma. Br J Haematol. 2017;178(2):250–256.
   PubMed Web of Science ®Google Scholar
• Derenzini E, Zinzani PL, Cheson BD. Bendamustine: role and evidence in lymphoma therapy, an overview. Leuk Lymphoma. 2014;55(7):1471–1478.
   PubMed Web of Science ®Google Scholar
• Gandhi V, Burger JA. Bendamustine in B-cell malignancies: the new 46-year-old kid on the block. Clin Cancer Res. 2009;15(24):7456–7461.
   PubMed Web of Science ®Google Scholar
• Leoni LM, Bailey B, Reifert J, et al. Bendamustine (Treanda) displays a distinct pattern of cytotoxicity and unique mechanistic features compared with other alkylating agents. Clin Cancer Res. 2008;14(1):309–317.
   PubMed Web of Science ®Google Scholar
• Chen YB, Lane AA, Logan B, et al. Impact of conditioning regimen on outcomes for patients with lymphoma undergoing high-dose therapy with autologous hematopoietic cell transplantation. Biol Blood Marrow Transplant. 2015;21(6):1046–1053.
   PubMed Web of Science ®Google Scholar
• Isidori A, Piccaluga PP, Loscocco F, et al. High-dose therapy followed by stem cell transplantation in Hodgkin's lymphoma: past and future. Expert Rev Hematol. 2013;6(4):451–464.
   PubMed Web of Science ®Google Scholar
• Visani G, Malerba L, Stefani PM, et al. BeEAM (bendamustine, etoposide, cytarabine, melphalan) before autologous stem cell transplantation is safe and effective for resistant/relapsed lymphoma patients. Blood. 2011;118(12):3419–3425.
   PubMed Web of Science ®Google Scholar
• Visani G, Stefani PM, Capria S, et al. Bendamustine, etoposide, cytarabine, melphalan, and autologous stem cell rescue produce a 72% 3-year PFS in resistant lymphoma. Blood. 2014;124(19):3029–3031.
   PubMed Web of Science ®Google Scholar
• Noesslinger T, Panny M, Simanek R, et al. High-dose Bendamustine-EAM followed by autologous stem cell rescue results in long-term remission rates in lymphoma patients, without renal toxicity. Eur J Haematol. 2018;101(3):326–331.
   PubMed Web of Science ®Google Scholar
• Redondo AM, Valcarcel D, Gonzalez-Rodriguez AP, et al.; Grupo Español de Linfomas y Trasplante Autólogo de Médula Ósea (GELTAMO). Bendamustine as part of conditioning of autologous stem cell transplantation in patients with aggressive lymphoma: a phase 2 study from the GELTAMO group. Br J Haematol. 2019;184(5):797–807.
   PubMed Web of Science ®Google Scholar
• Gomez-Arteaga A, Mark TM, Guarneri D, et al. High-dose bendamustine and melphalan conditioning for autologous stem cell transplantation for patients with multiple myeloma. Bone Marrow Transplant. 2019;54(12):2027–2038.
   PubMed Web of Science ®Google Scholar
• Srour SA, Li S, Popat UR, et al. A randomized phase II study of standard-dose versus high-dose rituximab with BEAM in autologous stem cell transplantation for relapsed aggressive B-cell non-hodgkin lymphomas: long term results. Br J Haematol. 2017;178(4):561–570.
   PubMed Web of Science ®Google Scholar
• Przepiorka D, van Besien K, Khouri I, et al. Carmustine, etoposide, cytarabine and melphalan as a preparative regimen for allogeneic transplantation for high-risk malignant lymphoma. Ann Oncol. 1999;10(5):527–532.
   PubMed Web of Science ®Google Scholar
• Faulkner RD, Craddock C, Byrne JL, et al. BEAM-alemtuzumab reduced-intensity allogeneic stem cell transplantation for lymphoproliferative diseases: GVHD, toxicity, and survival in 65 patients. Blood. 2004;103(2):428–434.
   PubMed Web of Science ®Google Scholar
• Hsu J, Artz A, Mayer SA, et al. Combined haploidentical and umbilical cord blood allogeneic stem cell transplantation for high-risk lymphoma and chronic lymphoblastic leukemia. Biol Blood Marrow Transplant. 2018;24(2):359–365.
   PubMed Web of Science ®Google Scholar
• Ghosh N, Ahmed S, Ahn KW, et al. Association of reduced-intensity conditioning regimens with overall survival among patients with non-hodgkin lymphoma undergoing allogeneic transplant. JAMA Oncol. 2020;6(7):1011–1018.
   PubMed Web of Science ®Google Scholar
• Ahmed S, Ghosh N, Ahn KW, et al. Impact of type of reduced-intensity conditioning regimen on the outcomes of allogeneic haematopoietic cell transplantation in classical Hodgkin lymphoma. Br J Haematol. 2020;190(4):573–582.
   PubMed Web of Science ®Google Scholar
• Bacher U, Klyuchnikov E, Le-Rademacher J, et al. Conditioning regimens for allotransplants for diffuse large B-cell lymphoma: myeloablative or reduced intensity? Blood. 2012;120(20):4256–4262.
   PubMed Web of Science ®Google Scholar
• Hsu J, Chen Z, Shore T, et al. Outcomes of allogeneic stem cell transplant for elderly patients with hematologic malignancies. Biol Blood Marrow Transplant. 2020;26(4):789–797.
   PubMed Web of Science ®Google Scholar
• Cheson BD, Pfistner B, Juweid ME, et al.; International Harmonization Project on Lymphoma. Revised response criteria for malignant lymphoma. J Clin Oncol. 2007;25(5):579–586.
   PubMed Web of Science ®Google Scholar
• Radivoyevitch T, Dean RM, Shaw BE, et al. Risk of acute myeloid leukemia and myelodysplastic syndrome after autotransplants for lymphomas and plasma cell myeloma. Leuk Res. 2018;74:130–136.
   PubMed Web of Science ®Google Scholar
• Khouri IF, Saliba RM, Hosing C, et al. Concurrent administration of high-dose rituximab before and after autologous stem-cell transplantation for relapsed aggressive B-cell non-Hodgkin's lymphomas. J Clin Oncol. 2005;23(10):2240–2247.
   PubMed Web of Science ®Google Scholar
• Jagadeesh D, Majhail NS, He Y, et al. Outcomes of rituximab-BEAM versus BEAM conditioning regimen in patients with diffuse large B cell lymphoma undergoing autologous transplantation. Cancer. 2020;126(10):2279–2287.
   PubMed Web of Science ®Google Scholar
• Singer S, Dean R, Zhao Q, et al. BEAM versus BUCYVP16 conditioning before autologous hematopoietic stem cell transplant in patients with hodgkin lymphoma. Biol Blood Marrow Transplant. 2019;25(6):1107–1115.
   PubMed Web of Science ®Google Scholar
• Schuster SJ, Bishop MR, Tam CS, et al.; JULIET Investigators. Tisagenlecleucel in adult relapsed or refractory diffuse large B-Cell lymphoma. N Engl J Med. 2019;380(1):45–56.
   PubMed Web of Science ®Google Scholar
• Neelapu SS, Locke FL, Bartlett NL, et al. Axicabtagene ciloleucel CAR T-cell therapy in refractory large B-cell lymphoma. N Engl J Med. 2017;377(26):2531–2544.
   PubMed Web of Science ®Google Scholar